(Q37713715)

22 August 2017

1 reference

title

Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites (English)

1 reference

22 August 2017

1 reference

St Peter JV

1

1 reference

PubMed ID

2029802

22 August 2017

Awni WM

series ordinal

2

1 reference

22 August 2017

1 January 1991

1 reference

Clinical Pharmacokinetics

22 August 2017

1 reference

22 August 2017

20

1 reference

22 August 2017

1

1 reference

22 August 2017

50-65

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199120010-00004

22 August 2017

0 references

cites work

Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.

1 reference

12 December 2020

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers

1 reference

12 December 2020

The antipyrine test in clinical pharmacology: Conceptions and misconceptions

1 reference

12 December 2020

Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

1 reference

12 December 2020

Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine

1 reference

12 December 2020

3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance

1 reference

12 December 2020

Interindividual variations in drug disposition. Clinical implications and methods of investigation

1 reference

12 December 2020

Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation

1 reference

12 December 2020

Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group

1 reference

12 December 2020

Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency

1 reference

12 December 2020

Pharmacokinetics of flecainide in patients with cirrhosis of the liver

1 reference

12 December 2020

Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis

1 reference

12 December 2020

Treatment of alcoholic cirrhosis with enzyme inducers

1 reference

12 December 2020

The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus

1 reference

12 December 2020

Kinetics of low-dose intravenous antipyrine: use of liquid chromatography

1 reference

12 December 2020

Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

1 reference

12 December 2020

Selection and interpretation of diagnostic tests and procedures. Principles and applications.

1 reference

12 December 2020

The use of antipyrine in the measurement of total body water in man

1 reference

12 December 2020

Antipyrine Absorption and Disposition in the Elderly

1 reference

12 December 2020

HPLC Determination of Antipyrine Metabolites

1 reference

12 December 2020

Is blood sampling for determination of antipyrine pharmacokinetics in healthy volunteers ethically justified?

1 reference

12 December 2020

Drugs as indicators of hepatic function.

1 reference

12 December 2020

Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver

1 reference

12 December 2020

Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration

1 reference

12 December 2020

Fibrotic process and drug metabolism in alcoholic liver disease

1 reference

12 December 2020

Modified high-performance liquid chromatographic assay for antipyrine and its three major metabolites in urine

1 reference

12 December 2020

Cirrhosis of the liver markedly impairs the elimination of mexiletine

1 reference

12 December 2020

Pharmacokinetics of antipyrine in epileptic patients

1 reference

12 December 2020

Assay of Antipyrine and Its Primary Metabolites in Plasma, Saliva and Urine by High-Performance Liquid Chromatography and Some Preliminary Results in Man

1 reference

12 December 2020

Pericellular collagen in alcoholics with liver cirrhosis

1 reference

12 December 2020

Simultaneous assay of antipyrine and its major metabolites in urine using high-performance liquid chromatography and on-line solid phase sample clean-up

1 reference

12 December 2020

Polymorphisms of antipyrine and theophylline metabolism in man: molecular and clinical implications

1 reference

12 December 2020

Determinants of serum antipyrine half-lives in patients with liver disease

1 reference

12 December 2020

Antipyrine kinetics in liver disease and liver transplantation

1 reference

12 December 2020

Advances in the application of biochemical tests to diseases of the liver and biliary tract: their role in diagnosis, prognosis, and the elucidation of pathogenetic mechanisms

1 reference

12 December 2020

Mucosal biotransformation

1 reference

12 December 2020

Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis

1 reference

12 December 2020

Application of salivary concentration data to pharmacokinetic studies with antipyrine

1 reference

12 December 2020

The estimation of antipyrine in biological materials

1 reference

12 December 2020

On the significance of host factors that affect drug disposition

1 reference

12 December 2020

Two compartment analysis of plasma elimination of phenazone in normals and in patients with cirrhosis of the liver

1 reference

12 December 2020

Functioning liver mass in uncomplicated and fulminant acute hepatitis

1 reference

12 December 2020

Drug metabolism in alcoholic liver disease

1 reference

12 December 2020

Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism

1 reference

12 December 2020

Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease

1 reference

12 December 2020

Accuracy and clinical utility of simplified tests of antipyrine metabolism

1 reference

12 December 2020

Prolongation of antipyrine half-life after correction of severe anaemia due to hookworm infestation

1 reference

12 December 2020

Spironolactone and enzyme induction in patients with alcoholic cirrhosis

1 reference

12 December 2020

Antipyrine as a model drug to study hepatic drug-metabolizing capacity

1 reference

12 December 2020

Altered elimination of antipyrine in patients with acute viral hepatitis

1 reference

12 December 2020

Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine

1 reference

12 December 2020

Factors influencing antipyrine elimination

1 reference

12 December 2020

Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease

1 reference

12 December 2020

Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time

1 reference

12 December 2020

The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate

1 reference

12 December 2020

Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in Man

1 reference

12 December 2020

Biliary excretion of antipyrine and its metabolites after cholecystectomy [letter]

1 reference

12 December 2020

Protein Binding and Kinetics of Drugs in Liver Diseases

1 reference

12 December 2020

Influence of the Genetically Controlled Deficiency in Debrisoquine Hydroxylation on Antipyrine Metabolite Formation

1 reference

12 December 2020

Influence of age and smoking on drug kinetics in man: studies using model compounds

1 reference

12 December 2020

Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice

1 reference

12 December 2020

Impairment of hepatic drug metabolism in patients with acute viral hepatitis

1 reference

12 December 2020

Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis

1 reference

12 December 2020

Genetically determined polymorphisms in drug oxidation

1 reference

12 December 2020

Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis

1 reference

12 December 2020

Rapid gas-liquid chromatographic estimation of antipyrine in plasma

1 reference

12 December 2020

Clearance of antipyrine-dependence of quantitative liver function.

1 reference

12 December 2020

The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease

1 reference

12 December 2020

Drug disposition in patients with HBsAg-positive chronic liver disease

1 reference

12 December 2020

Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state

1 reference

12 December 2020

Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.

1 reference

12 December 2020

Disorders of biotransformation during the progression of alcoholic liver disease

1 reference

12 December 2020

Improved high-performance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine

1 reference

12 December 2020

Increased susceptibility to liver disease in relation to alcohol consumption in women

1 reference

12 December 2020

Influence of age and consumption of tobacco, alcohol and caffeine on antipyrine clearance

1 reference

12 December 2020

The absence of significant biliary excretion of antipyrine or its metabolites in humans

1 reference

12 December 2020

Bioavailability and elimination of nitrendipine in liver disease

1 reference

12 December 2020

Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease

1 reference

12 December 2020

Antipyrine elimination in patients with obstructive jaundice: a predictor of outcome

1 reference

12 December 2020

Disappearance of phenazone from plasma in patients with obstructive jaundice

1 reference

12 December 2020

Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases

1 reference

12 December 2020

10.2165/00003088-199120010-00004

Identifiers

DOI

1 reference

PubMed ID

2029802

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

2029802